Yushi Chikasawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yushi Chikasawa has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Kagehiro Amano
Tokyo Medical University, Tokyo, Japan
9 shared publicationsTakeshi Hagiwara
7 shared publicationsKatsuyuki Fukutake
Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan
4 shared publicationsMasato Bingo
Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan
4 shared publicationsAkito Ichiki
3 shared publications- Azusa Nagao
Department of Hematology and Oncology Kansai Medical University Hospital Osaka Japan
3 shared publications
Latest Publications
- 30 September 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (11)
Aspergillus tubingensis pneumonia with pulmonary oxalosis in a virologically suppressed person with HIV: A case report
- 30 September 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (11)
Aspergillus tubingensis pneumonia with pulmonary oxalosis in a virologically suppressed person with HIV: A case report
- Open Access
- 23 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5789-5799
Cardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort
As the life expectancy of individuals with hemophilia increases, arterial thrombotic disease has emerged as an important clinical issue. Accurate risk stratification for primary prevention is increasingly critical, since managing arterial events is complex in hemophilia owing to bleeding risk. However, current prospective data on event incidence and risk prediction for hemophilia remain limited. We analyzed 5-year follow-up data from ADVANCE Japan-a nationwide prospective registry of Japanese adults aged ≥40 years with hemophilia. Participants with prior arterial thrombosis were excluded. Five-year arterial event risk was estimated using the Hisayama model, the Suita score, and QRISK3. Model performance was evaluated using sensitivity, specificity, and observed-to-expected event comparisons. Among the 599 participants (median age: 59 years; 83% hemophilia A, 63% severe disease), 28 first arterial events occurred over 5 years (4.67%). The sensitivity and specificity for identifying events were 70.5% and 68.0% for the Hisayama model, 73.3% and 61.2% for the Suita score, and 71.4% and 57.7% for QRISK3, respectively. The observed incidence was 2.93 events per 100 participants over 5 years, closely matching predictions by the Hisayama model and Suita score, whereas QRISK3 substantially overestimated the risk. Incorporating hemophilia-related clinical factors did not improve predictive performance beyond established scores. Arterial event incidence in Japanese adults with hemophilia was comparable to that expected in the Japanese general population. The Japanese population-based risk models-the Hisayama model-may support the development of primary prevention strategies for Japanese adults with hemophilia. This trial was registered with the Japan Registry of Clinical Trials (jRCT1030190046).
- 23 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5789-5799
Open AccessCardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort
As the life expectancy of individuals with hemophilia increases, arterial thrombotic disease has emerged as an important clinical issue. Accurate risk stratification for primary prevention is increasingly critical, since managing arterial events is complex in hemophilia owing to bleeding risk. However, current prospective data on event incidence and risk prediction for hemophilia remain limited. We analyzed 5-year follow-up data from ADVANCE Japan-a nationwide prospective registry of Japanese adults aged ≥40 years with hemophilia. Participants with prior arterial thrombosis were excluded. Five-year arterial event risk was estimated using the Hisayama model, the Suita score, and QRISK3. Model performance was evaluated using sensitivity, specificity, and observed-to-expected event comparisons. Among the 599 participants (median age: 59 years; 83% hemophilia A, 63% severe disease), 28 first arterial events occurred over 5 years (4.67%). The sensitivity and specificity for identifying events were 70.5% and 68.0% for the Hisayama model, 73.3% and 61.2% for the Suita score, and 71.4% and 57.7% for QRISK3, respectively. The observed incidence was 2.93 events per 100 participants over 5 years, closely matching predictions by the Hisayama model and Suita score, whereas QRISK3 substantially overestimated the risk. Incorporating hemophilia-related clinical factors did not improve predictive performance beyond established scores. Arterial event incidence in Japanese adults with hemophilia was comparable to that expected in the Japanese general population. The Japanese population-based risk models-the Hisayama model-may support the development of primary prevention strategies for Japanese adults with hemophilia. This trial was registered with the Japan Registry of Clinical Trials (jRCT1030190046).
- Open Access
A Retrospective Cohort Study on HHV-8 Viral Load and Prognosis in HIV-Associated Kaposi Sarcoma Among People Living with HIV in Japan
Background: The characteristics and prognosis of HIV-associated Kaposi sarcoma (KS) among people living with HIV (PLWH), and their association with HHV-8 viral load are not well understood in Japan. Methods: We conducted a retrospective study of PLWH diagnosed with KS at Tokyo Medical University from 2000 to 2023. Results: Seventy cases of KS were identified; HHV-8 viral load data were available for twenty-three of these cases. The median age was 43 years (interquartile range [IQR], 11 years). The median HIV viral load at diagnosis was 150,000 copies/mL (IQR, 560,000 copies/mL). The median CD4 count was 76.0/μL (IQR, 157/μL). Lesions other than those of the skin were observed in the gastrointestinal tract (nine cases, 39.1%), oropharynx (three cases, 13.0%), and bronchial/lung (two cases, 8.7%). The median HHV-8 viral load was 0.0 copies/106 WBC (IQR, 1500 copies/106 WBC). Among the nine deceased PLWH, KS inflammatory cytokine syndrome (KICS) was diagnosed in five PLWH. Older age (≥50 years) and a high HHV-8 viral load (>615 copies/106 WBCs) were significantly associated with worse survival. Conclusion: A high HHV-8 viral load may be a risk factor for mortality in PLWH with KS. Notably, all PLWH diagnosed with KICS in this study died, underscoring the poor prognosis associated with this condition.
Open AccessA Retrospective Cohort Study on HHV-8 Viral Load and Prognosis in HIV-Associated Kaposi Sarcoma Among People Living with HIV in Japan
Background: The characteristics and prognosis of HIV-associated Kaposi sarcoma (KS) among people living with HIV (PLWH), and their association with HHV-8 viral load are not well understood in Japan. Methods: We conducted a retrospective study of PLWH diagnosed with KS at Tokyo Medical University from 2000 to 2023. Results: Seventy cases of KS were identified; HHV-8 viral load data were available for twenty-three of these cases. The median age was 43 years (interquartile range [IQR], 11 years). The median HIV viral load at diagnosis was 150,000 copies/mL (IQR, 560,000 copies/mL). The median CD4 count was 76.0/μL (IQR, 157/μL). Lesions other than those of the skin were observed in the gastrointestinal tract (nine cases, 39.1%), oropharynx (three cases, 13.0%), and bronchial/lung (two cases, 8.7%). The median HHV-8 viral load was 0.0 copies/106 WBC (IQR, 1500 copies/106 WBC). Among the nine deceased PLWH, KS inflammatory cytokine syndrome (KICS) was diagnosed in five PLWH. Older age (≥50 years) and a high HHV-8 viral load (>615 copies/106 WBCs) were significantly associated with worse survival. Conclusion: A high HHV-8 viral load may be a risk factor for mortality in PLWH with KS. Notably, all PLWH diagnosed with KICS in this study died, underscoring the poor prognosis associated with this condition.
- Open Access
- 10 April 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (3)
Comparison of genotypes and phenotypes for von Willebrand factor gene variants using Japanese genome database
- 10 April 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (3)
Open AccessComparison of genotypes and phenotypes for von Willebrand factor gene variants using Japanese genome database
- Open Access
- 1 January 2025
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 36 (1) , 10-17
Hemophilia advocacy
稀少疾患である血友病の治療薬は初期の頃から高額であり,費用負担の軽減や治療アクセスの拡大が重要な課題であった.患者アドボカシーとは,患者やその家族が医療政策に影響を与えるために自らの権利やニーズを主張する活動であるが,まさに1960~80年代の患者会によるアドボカシー活動は盛んであった.その結果,種々の権利が獲得されつつあった1980年代に薬害エイズ事件が起こり,血友病患者会としての集合が難しくなった一方で,同事件を契機に血友病の治療費は完全に公費負担となった.その後も血友病治療薬の開発は進み,定期補充療法で健常人に近い日常生活が可能となってきたが,依然として治療コストは高く,本邦の医療経済に大きな影響がある.2024年現在,改めて血友病患者が団結し,アドボカシー活動を継続する意義とその必要性や方法について,同年大阪で開催されたHABIT summitの内容を踏まえてここで考察する.
- 1 January 2025
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 36 (1) , 10-17
Open AccessHemophilia advocacy
稀少疾患である血友病の治療薬は初期の頃から高額であり,費用負担の軽減や治療アクセスの拡大が重要な課題であった.患者アドボカシーとは,患者やその家族が医療政策に影響を与えるために自らの権利やニーズを主張する活動であるが,まさに1960~80年代の患者会によるアドボカシー活動は盛んであった.その結果,種々の権利が獲得されつつあった1980年代に薬害エイズ事件が起こり,血友病患者会としての集合が難しくなった一方で,同事件を契機に血友病の治療費は完全に公費負担となった.その後も血友病治療薬の開発は進み,定期補充療法で健常人に近い日常生活が可能となってきたが,依然として治療コストは高く,本邦の医療経済に大きな影響がある.2024年現在,改めて血友病患者が団結し,アドボカシー活動を継続する意義とその必要性や方法について,同年大阪で開催されたHABIT summitの内容を踏まえてここで考察する.
- 23 May 2024
- Published by Wiley in Haemophilia
- Vol. 30 (4) , 933-942
Treatment of thrombotic cardiovascular diseases in people with haemophilia: A Japanese consensus study
Introduction: Cardiovascular diseases (CVD) that require long‐term anticoagulant and antiplatelet therapy presents a problem in people with haemophilia (PWH) who receive factor replacement therapy to reduce bleeding risk. Currently, there are no Japanese guidelines for the management of PWH with CVD.Aim: To develop expert guidance on managing CVD in PWH in Japan.Methods: A steering committee of four experts (two haemophilia specialists, one thrombosis specialist, one cardiologist) identified 44 statements related to five key themes. An online questionnaire was produced comprising a mix of 4‐point Likert scale and multiple‐choice questions that was sent to specialists in the management of PWH with CVD in Japan. Consensus was defined as high or very high if a respective ≥75% or ≥90% of respondents agreed with a statement.Results: Of 16 potential respondents, responses were received from 15 specialists. Of the Likert scale questions, 71% (29/41) achieved ≥90% agreement (very strong agreement), 17% (7/41) achieved 75%–89% agreement (strong agreement) and 15% (6/41) did not achieve consensus agreement. The three multiple‐choice questions failed to identify a strong preference. Agreement on specific target trough clotting factor levels for managing certain clinical situations, such as when in the presence of non‐valvular atrial fibrillation or myocardial infarction, was also achieved.Conclusion: The results of this consensus study provide a framework for cardiologists and haematologists to manage PWH who are at risk of, or who have, CVD. Implementation of the recommendations provided herein may improve outcomes for PWH with CVD.
- 23 May 2024
- Published by Wiley in Haemophilia
- Vol. 30 (4) , 933-942
Treatment of thrombotic cardiovascular diseases in people with haemophilia: A Japanese consensus study
Introduction: Cardiovascular diseases (CVD) that require long‐term anticoagulant and antiplatelet therapy presents a problem in people with haemophilia (PWH) who receive factor replacement therapy to reduce bleeding risk. Currently, there are no Japanese guidelines for the management of PWH with CVD.Aim: To develop expert guidance on managing CVD in PWH in Japan.Methods: A steering committee of four experts (two haemophilia specialists, one thrombosis specialist, one cardiologist) identified 44 statements related to five key themes. An online questionnaire was produced comprising a mix of 4‐point Likert scale and multiple‐choice questions that was sent to specialists in the management of PWH with CVD in Japan. Consensus was defined as high or very high if a respective ≥75% or ≥90% of respondents agreed with a statement.Results: Of 16 potential respondents, responses were received from 15 specialists. Of the Likert scale questions, 71% (29/41) achieved ≥90% agreement (very strong agreement), 17% (7/41) achieved 75%–89% agreement (strong agreement) and 15% (6/41) did not achieve consensus agreement. The three multiple‐choice questions failed to identify a strong preference. Agreement on specific target trough clotting factor levels for managing certain clinical situations, such as when in the presence of non‐valvular atrial fibrillation or myocardial infarction, was also achieved.Conclusion: The results of this consensus study provide a framework for cardiologists and haematologists to manage PWH who are at risk of, or who have, CVD. Implementation of the recommendations provided herein may improve outcomes for PWH with CVD.
- 8 October 2023
- Published by Wiley in Haemophilia
- Vol. 29 (6) , 1519-1528
Haemophilia and cardiovascular disease in Japan: Low incidence rates from ADVANCE Japan baseline data
Introduction: With the increasing life expectancy of people with haemophilia, the risk of cardiovascular disease (CVD) and thrombotic events has become a growing concern. Longitudinal studies on the incidence and risk factors of CVD in this population are limited, and optimal prevention and treatment strategies are yet to be established.Aim: This study aimed to present the baseline data of a prospective longitudinal study focusing on a subset of Japanese patients with haemophilia, specifically investigated the incidence, risk factors and treatment modalities for CVD and thrombotic diseases in people aged 40 years in Japan over 10 years through the ADVANCE Japan study.Methods: The ADVANCE Japan study is a prospective multicentre cohort study involving 600 adult individuals with haemophilia A/B aged 40 years in Japan. The primary endpoint was the incidence of CVD, with secondary endpoints encompassing anticoagulant use, mortality rates, and comparison with the general population.Results: Baseline data from the 600 participants revealed that thrombotic events occurred in 13 individuals (2.2%), mostly in those with haemophilia A. Atrial fibrillation was observed in 11 participants (1.8%). Hypertension and dyslipidaemia were identified as the prevalent risk factors. Various prophylactic treatments were employed, and no severe bleeding events were observed during the study period.Conclusion: This study provides vital baseline data for a 10‐year prospective investigation of CVD and thrombotic disease risk in people with haemophilia. These findings will contribute to refining prevention and treatment approaches and improving patients’ quality of life.
- 8 October 2023
- Published by Wiley in Haemophilia
- Vol. 29 (6) , 1519-1528
Haemophilia and cardiovascular disease in Japan: Low incidence rates from ADVANCE Japan baseline data
Introduction: With the increasing life expectancy of people with haemophilia, the risk of cardiovascular disease (CVD) and thrombotic events has become a growing concern. Longitudinal studies on the incidence and risk factors of CVD in this population are limited, and optimal prevention and treatment strategies are yet to be established.Aim: This study aimed to present the baseline data of a prospective longitudinal study focusing on a subset of Japanese patients with haemophilia, specifically investigated the incidence, risk factors and treatment modalities for CVD and thrombotic diseases in people aged 40 years in Japan over 10 years through the ADVANCE Japan study.Methods: The ADVANCE Japan study is a prospective multicentre cohort study involving 600 adult individuals with haemophilia A/B aged 40 years in Japan. The primary endpoint was the incidence of CVD, with secondary endpoints encompassing anticoagulant use, mortality rates, and comparison with the general population.Results: Baseline data from the 600 participants revealed that thrombotic events occurred in 13 individuals (2.2%), mostly in those with haemophilia A. Atrial fibrillation was observed in 11 participants (1.8%). Hypertension and dyslipidaemia were identified as the prevalent risk factors. Various prophylactic treatments were employed, and no severe bleeding events were observed during the study period.Conclusion: This study provides vital baseline data for a 10‐year prospective investigation of CVD and thrombotic disease risk in people with haemophilia. These findings will contribute to refining prevention and treatment approaches and improving patients’ quality of life.
- 26 September 2023
- Published by Springer Nature in International Journal of Hematology
- Vol. 118 (5) , 577-588
Comprehensive comparison of global coagulation assays to differentiate lupus anticoagulant from acquired hemophilia A in patients with prolonged APTT
There is no established method for differentiating acquired hemophilia A (AHA) from lupus anticoagulant (LA) positivity because both present with prolonged activated partial thromboplastin time. We compared various parameters of rotational thromboelastometry (ROTEM), thrombin generation assay (TGA), and clot waveform analysis (CWA) in patients with AHA (n = 10) and LA (n = 44). Compared with AHA, possible (n = 12) and definite (n = 32) LA showed significantly shorter clotting time (CT) in NATEM mode of ROTEM (> 3600 vs. 501/533). In TGA, peak height was significantly lower in AHA (16 vs. 242/174 nM). In CWA, CT was significantly longer (81 vs. 36/41 s) and Ad|min1| was lower (2.1 vs. 8.7/6.7) in AHA. Notably, CT by NATEM and peak height in TGA completely discriminated between AHA and LA, whereas Ad|min1| did not discriminate between them in 4 cases of AHA and 1 of LA. Comparison of 3 patients with both AHA and LA against a patient with only LA and markedly low FVIII activity (3.5%) showed that both CT by NATEM and peak height of TGA precisely classified the former 3 cases as AHA and the latter 1 case as LA, whereas Ad|min1| classified all 4 cases as AHA. ROTEM and TGA can comparably distinguish between AHA and LA.
- 26 September 2023
- Published by Springer Nature in International Journal of Hematology
- Vol. 118 (5) , 577-588
Comprehensive comparison of global coagulation assays to differentiate lupus anticoagulant from acquired hemophilia A in patients with prolonged APTT
There is no established method for differentiating acquired hemophilia A (AHA) from lupus anticoagulant (LA) positivity because both present with prolonged activated partial thromboplastin time. We compared various parameters of rotational thromboelastometry (ROTEM), thrombin generation assay (TGA), and clot waveform analysis (CWA) in patients with AHA (n = 10) and LA (n = 44). Compared with AHA, possible (n = 12) and definite (n = 32) LA showed significantly shorter clotting time (CT) in NATEM mode of ROTEM (> 3600 vs. 501/533). In TGA, peak height was significantly lower in AHA (16 vs. 242/174 nM). In CWA, CT was significantly longer (81 vs. 36/41 s) and Ad|min1| was lower (2.1 vs. 8.7/6.7) in AHA. Notably, CT by NATEM and peak height in TGA completely discriminated between AHA and LA, whereas Ad|min1| did not discriminate between them in 4 cases of AHA and 1 of LA. Comparison of 3 patients with both AHA and LA against a patient with only LA and markedly low FVIII activity (3.5%) showed that both CT by NATEM and peak height of TGA precisely classified the former 3 cases as AHA and the latter 1 case as LA, whereas Ad|min1| classified all 4 cases as AHA. ROTEM and TGA can comparably distinguish between AHA and LA.
- 9 May 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (4) , 622-629
Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report
Type 3 von Willebrand disease (VWD), a rare and severe subtype, can produce inhibitors in roughly 5% to 10% of cases. We present a case of type 3 VWD with inhibitors in late pregnancy, which was successfully managed with a combination of neutralization and factor (F)VIII replacement during cesarean delivery. The patient, a 30-year-old woman, had no history of inhibitors despite over 100 exposures to VWF/FVIII. She developed inhibitors after 28 weeks of weekly pd VWF/FVIII prophylaxis for recurrent urolithiasis-associated hematuria during pregnancy. Genetic analysis detected two novel frameshift mutations: VWF Exon7 c.777_784dup and Exon14 c.1625_1646del. Titers of inhibitors to factors VIII and VWF using the Bethesda assay were 1.2 and 1.1 BU/mL, respectively. Pharmacokinetics revealed significantly low in vivo recovery of FVIII:C and VWF:Rcof and shortened half-life. During cesarean delivery, a combination of bolus pd VWF/FVIII once daily for neutralizing inhibitors plus continuous infusion of recombinant FVIII Fc fusion protein resulted in minimal bleeding without allergic reactions. Both VWF:Rcof and FVIII:C levels increased transiently during the 7-h of combination therapy without thrombotic events. In conclusion, combination therapy with neutralization and continuous FVIII replacement was effective for hemostasis with a low VWD inhibitor titer, though further optimization is required.
- 9 May 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (4) , 622-629
Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report
Type 3 von Willebrand disease (VWD), a rare and severe subtype, can produce inhibitors in roughly 5% to 10% of cases. We present a case of type 3 VWD with inhibitors in late pregnancy, which was successfully managed with a combination of neutralization and factor (F)VIII replacement during cesarean delivery. The patient, a 30-year-old woman, had no history of inhibitors despite over 100 exposures to VWF/FVIII. She developed inhibitors after 28 weeks of weekly pd VWF/FVIII prophylaxis for recurrent urolithiasis-associated hematuria during pregnancy. Genetic analysis detected two novel frameshift mutations: VWF Exon7 c.777_784dup and Exon14 c.1625_1646del. Titers of inhibitors to factors VIII and VWF using the Bethesda assay were 1.2 and 1.1 BU/mL, respectively. Pharmacokinetics revealed significantly low in vivo recovery of FVIII:C and VWF:Rcof and shortened half-life. During cesarean delivery, a combination of bolus pd VWF/FVIII once daily for neutralizing inhibitors plus continuous infusion of recombinant FVIII Fc fusion protein resulted in minimal bleeding without allergic reactions. Both VWF:Rcof and FVIII:C levels increased transiently during the 7-h of combination therapy without thrombotic events. In conclusion, combination therapy with neutralization and continuous FVIII replacement was effective for hemostasis with a low VWD inhibitor titer, though further optimization is required.
- 22 July 2020
- Published by Wiley in Haemophilia
- Vol. 27 (1) , E143-E146
Safety and blood loss in spinal surgery for haemophiliacs: Case series of Japanese haemophiliacs
- 22 July 2020
- Published by Wiley in Haemophilia
- Vol. 27 (1) , E143-E146
Safety and blood loss in spinal surgery for haemophiliacs: Case series of Japanese haemophiliacs